Abstract: An ozone generator generates ozone gas; a gas-liquid mixer mixes the ozone gas and a liquid; a liquid storage tank separates an introduced gas-liquid mixture into gas and a liquid; a circulation path circulates gas among the ozone generator, the gas-liquid mixer and the liquid storage tank; and an opening and closing control means controls a flow of gas flowing out through a gas outlet port of the liquid storage tank in accordance with a stored liquid amount in the liquid storage tank. As a result, the stored liquid amount of the liquid stored in the liquid storage tank can be adjusted.

Abstract: In a radio communication system in which a base station and a terminal communicate with each other, the base station efficiently transmits control information to the terminal. The base station that communicates with the terminal using resource blocks, each of which is constituted by a prescribed time region and a prescribed frequency region, includes a terminal-specific control channel generation unit that generates terminal-specific control channels mapped in a terminal-specific control channel region constituted by a prescribed number of resource blocks and transmitted using the same antenna port as for terminal-specific reference signals, which are reference signals specific to the terminal.

Abstract: The invention provides expression vectors that support high levels of polypeptide expression in mammalian cells. The vectors contain at least one expression cassette for a target polypeptide; an expression cassette for a eukaryotic selectable marker protein; an expression cassette for a bacterial selectable marker protein, and a bacterial plasmid origin of replication.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

Abstract: The present invention provides a CHO cell that includes a polynucleotide encoding a polypeptide of interest. The CHO cell may include a heterologous polynucleotide encoding IL6 and/or an IL6 pathway member or, in the absence of the heterologous IL6 or an IL6 pathway member polynucleotide, the CHO cell can be cultured in the presence of exogenously added IL6 polypeptide. Such CHO cells exhibit superior expression of the polypeptide of interest in culture. Methods for expressing a polypeptide of interest and methods for making such CHO cells are part of the present invention.

Abstract: Provided is a liquid crystal display device capable of reliably reducing power consumption during pause drive by controlling the timing of performing refresh. When there is an image change in externally inputted RGB data, or when the number of consecutive pause frames reaches a predetermined value, if the number of immediately preceding pause frames is less than a threshold BCTH, image signal refresh is performed once, or if the number of pause frames is greater than or equal to the threshold BCTH, boost charge refresh is performed first, and then, the image signal refresh is performed. As a result, it is rendered possible to reduce flicker due to luminance reduction, and it is also rendered possible to eliminate the need to perform refresh consecutively even if the frequency of RGB data is high (e.g., 30 Hz) during pause drive.

Abstract: Immediate-release formulations for oral administration of a thrombin receptor antagonist are provided. Certain formulations of higher API loading demonstrate sufficient moisture uptake after storage at stressed conditions to retard dissolution. The formulations of the present invention incorporate either lower API loading or elevated disintegrant-to-API ratios, found necessary to achieve disintegration rates required for immediate-release performance.

Abstract: The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.

Abstract: There is provided a liquid crystal display device which is capable of reducing power consumption while preventing liquid crystal deterioration. The liquid crystal display device performs an intermission driving. The liquid crystal display device includes a polarity indication section, which controls a driving section included in the liquid crystal display device so that the data voltages to be written to the pixel formation portions in a first refreshing frame included in the drive period have a same polarity as of the data voltages written to the pixel formation portions in the refreshing frame immediately preceding the first refreshing frame and that the data voltage polarity is inverted for each refreshing frame during the drive period, if the drive period includes an even number of the refreshing frames.

Abstract: A mobile station device transmits a transport block in an uplink subframe. The mobile station device delivers acknowledgement (ACK) for the transport block to higher layers in a case that the transport block was transmitted by the mobile station device to a base station device and the transport block is disabled based on a physical downlink control channel received in a downlink subframe.

Abstract: A display device includes: a display unit having a rectangular display area; a touch panel on the display unit; and a processor configured to perform the following: causing a character image to be displayed in a determination area located in a corner of the display area such that the character image contacts two sides of the determination area that border an exterior of the display area; determining whether a hand gripping the touch pen is a left hand or a right hand in accordance with input locations of the touch pen on the character image and a display location of the character image; detecting a shift amount in accordance with the input locations of the touch pen on the character image and the display location of the character image; and correcting an input location of the touch pen in the display area in accordance with the detected shift amount.

Abstract: Obtained is a configuration of a stereoscopic display device wherein luminance variation and increase of crosstalk can be reduced over a period before and after the switching of the parallax barrier. The stereoscopic display device includes: a display panel for displaying an image with a plurality of pixels; a switch liquid crystal panel that is arranged so as to be stacked on the display panel; a position sensor for acquiring position information of a viewer; and a control unit for moving a parallax barrier in which transmitting regions and non-transmitting regions are formed in periodic fashion in a predetermined alignment direction, in such a manner that the parallax barrier is moved in the predetermined alignment direction in accordance with the position information, with use of a predetermined barrier switching pitch as a minimum unit, and causing the switch liquid crystal panel to display the parallax barrier.

Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Abstract: The present invention provides a vapor deposition apparatus capable of preventing abnormal film formation due to scattering in vapor deposition streams; and a method for producing an organic electroluminescent element which includes forming a patterned thin film with the vapor deposition apparatus. The present invention relates to a vapor deposition apparatus that includes a vapor deposition source equipped with a nozzle that ejects vapor deposition particles; an integrated limiting plate equipped with a first limiting plate including an opening that is in front of the nozzle, and with second limiting plates placed in the opening in the first limiting plate; and a mask including slits. The present invention also relates to a method for producing electroluminescent elements that includes a vapor deposition step of forming a patterned thin film with the vapor deposition apparatus.

Abstract: A touch panel controller (1) includes a first capacitance distribution calculation unit (15) that outputs a first signal value map which indicates a distribution of signal values in a touch panel (10) and a first capacitance distribution correction unit (16) that configures a broader area than an area in which changes in the signal values due to an input operation on the touch panel occur on the first signal value map, performs correction calculation that cancels the changes in the signal values due to external factors which are different from the input operation on the touch panel in the region, and generates a second signal value map.

Abstract: A backlight unit 12 includes a chassis 14, an LED 17, a light guide plate 19, a duct member 22, and dissipative LED attachment portion 30. The chassis 14 includes a light exit portion 14c through which light exits. The LED 17 is arranged close to an end portion of the chassis 14. The light guide plate 19 is arranged closer to a middle area of the chassis 14 than the LED 17 and light from the LED 17 is guided toward the light exit portion 14c thereby. The duct member 22 is arranged on the side opposite to the light exit portion 14c side of the chassis 14 and has an air passage 23 therein. The duct member 22 is formed of a composite plate 37 including a resin core 38 having a plate-like shape and a pair of metal plates 39 and 40 arranged so as to sandwich the resin core 38 from a front side and a rear side.

Abstract: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Q is a bond or —N(R5)—; T is a bond, —O—, —C(O)—; S, —N(R5)—, or —C(R6?R7?); U is a bond or —C(R6)(R7)— Y is C or N; Z is C or N; ring A, including variables Y and Z, is a three to nine membered cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, and heteroaryl ring having 0 to 4, preferably 0 to 2, heteroatoms independently selected from the group consisting of O, S, N and —N(R)—, wherein ring A is unsubstituted or substituted with 1 to 5 independently selected R1 moieties and/or oxo when ring A is cycloalkyl, cycloalkenyl, heterocyclyl or heterocyclenyl; and R, R1, R2, R3, R4, R5, R6, R6, R7 and R7? are as defined in the specification; pharmaceutical compositions comprising the compounds of formula I and the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases.

Abstract: Described herein is a process for preparing nano-suspensions, wherein the process comprises: providing an admixture of at least one active pharmaceutical compound, an aqueous dispersion medium, and milling media and applying thereto acoustic energy having a frequency of from about 10 hertz to 1000 hertz and which supplies a linear acceleration of from about 10 G's to about 100 G's (where “G” is the force of gravity) for a period sufficient to supply a nano-suspension having a D50 of less than about 1 micron, preferably less than about 500 nm. Described also are nano-suspensions having novel properties prepared via the inventive process.

Abstract: Provided are a mounting member which may be fixed to a substrate with a simple structure without using a solder, and easily mount the substrate to another member having a simple structure, while maintaining stable fixation to the substrate, a display device including the mounting member, and a television receiver including the display device. The mounting member includes a first abutting plate part formed in a square flat shape, a side abutting plate part connected to the first abutting plate part at a right angle, and a second abutting plate part connected to the side abutting plate part at a right angle. The mounting member is mounted so as to pinch a portion of an edge part of the substrate. The other member abuts the first abutting plate part, and a screw is inserted into a screw insertion hole of the other member, the screw insertion hole of the first abutting plate part, and the screw insertion hole of the substrate, and screwed to a female thread such that the substrate is mounted to the other member.

Abstract: A transition metal hexacyanoferrate (TMH) cathode battery is provided. The battery has a AxMn[Fe(CN)6]y.zH2O cathode, where the A cations are either alkali or alkaline-earth cations, such as sodium or potassium, where x is in the range of 1 to 2, where y is in the range of 0.5 to 1, and where z is in the range of 0 to 3.5. The AxMn[Fe(CN)6]y.zH2O has a rhombohedral crystal structure with Mn2+/3+ and Fe2+/3+ having the same reduction/oxidation potential. The battery also has an electrolyte, and anode made of an A metal, an A composite, or a material that can host A atoms. The battery has a single plateau charging curve, where a single plateau charging curve is defined as a constant charging voltage slope between 15% and 85% battery charge capacity. Fabrication methods are also provided.